Health Decisions

Health Decisions' new Strategic Development Division aligns the interests of pharmaceutical companies, medical device companies, and patients with a risk-sharing model that accelerates clinical development through fixed-price investments and incentive-based performance.

On average, only 10 percent of traditional clinical research studies enroll on time, and most go over budget by 30 percent or more. Traditional CROs using the time and materials business model have little incentive to complete a study on time and are actually rewarded the longer the study takes, resulting in more revenue for the CRO.

Health Decisions' fixed-price strategy provides a single price for the entire program, enabling sponsors the financial security of predictable cash flow and the assurance of no cost overruns. Most importantly, Health Decisions becomes a business partner by aligning its goals with those of the client to get products to market faster.

This division was established as an evolutionary progression in Health Decisions’ strategic approach to clinical development. These strategic partnerships are enabled through Agile Clinical Development which takes adaptive research a step further by integrating adaptive design, adaptive operations and Health Decisions' HD360° proprietary technology platform, to target every source of inefficiency in clinical research - from design elements to the day-to-day operational pain points. Our approach recognizes the increasing demand for comprehensive services whose value is measured at the bottom line, by time to market, NPV and IRR. Health Decision is the only CRO who effectively integrates all three elements of adaptive research to gaurentee these results.